HMG CoA reductase inhibitors and renoprotection: the weight of the evidence (Q37362681)

19 August 2017

1 reference

title

HMG CoA reductase inhibitors and renoprotection: the weight of the evidence (English)

1 reference

19 August 2017

L Romayne Kurukulasuriya

1

1 reference

19 August 2017

Ganesh Athappan

2

1 reference

19 August 2017

Georges Saab

3

1 reference

19 August 2017

Adam Whaley Connell

4

1 reference

19 August 2017

James R Sowers

5

1 reference

19 August 2017

1 October 2007

1 reference

Therapeutic advances in cardiovascular disease

19 August 2017

1 reference

19 August 2017

1

1 reference

19 August 2017

1

1 reference

19 August 2017

49-59

1 reference

Controlling oxidative stress as a novel molecular approach to protecting the vascular wall in diabetes

19 August 2017

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Study of Heart and Renal Protection (SHARP)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Premature cardiovascular disease in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Apolipoprotein A-IV predicts progression of chronic kidney disease: the mild to moderate kidney disease study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Dyslipidemia and the progression of renal disease in chronic renal failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Pravastatin suppress superoxide and fibronectin production of glomerular mesangial cells induced by oxidized-LDL and high glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Expression of scavenger receptor CD36 in chronic renal failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Mechanisms of NADPH oxidase activation in human neutrophils: p67phox is required for the translocation of rac 1 but not of rac 2 from cytosol to the membranes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors on renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Why do we need a statin trial in hemodialysis patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Effect of lipid reduction on the progression of renal disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Transcription factor-kappa B (NF-kappa B) and renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

An assessment of statin safety by nephrologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Effect of pravastatin on proteinuria in patients with well-controlled hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Effects of HMG-CoA reductase inhibitors on endothelial function: role of microdomains and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

The dyslipidemia of chronic renal disease: effects of statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Statins for improving renal outcomes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Preventi

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Lp(a) glycoprotein phenotypes. Inheritance and relation to Lp(a)-lipoprotein concentrations in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

21 January 2018

Statins and proteinuria

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Rosuvastatin-induced arrest in progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Albumin activation of NAD(P)H oxidase activity is mediated via Rac1 in proximal tubule cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Endothelium-dependent effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1753944707082714

21 January 2018

Identifiers

DOI

10.1177/1753944707082714

1 reference

19 August 2017

1 reference